Clinical trials: Infusion Reaction
Hairy Cell Leukemia
US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)
This study is being conducted to satisfy a post-marketing requirement (PMR) to provide evidence characterizing 1) the safety of moxetumomab pasudotox-tdfk in patients who are 65 years of age and older and/or 2) the safety of…
- Trial name
- PROXY (NCT04125290)
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- AstraZeneca
Hemodynamic Response, Acute Appendicitis
Lidocaine VS Hemodynamic, Metabolic and Hormonal Response
Intravenous lidocaine - a potent local anesthetic with analgesic and anti- inflammatory properties has been shown to be an effective adjunct that reduces intra and postoperative opioid consumption and facilitates pain management…
- Conditions
- Hemodynamic Response, Acute Appendicitis, Complication of Treatment, Opioid Consumption
- Trial name
- NCT05238506
- Testing
- Intravenous lidocaine, Normal saline infusion
- Where
- Poland
- Volunteers
- 132 people
- Sponsor
- Medical University of Warsaw
Inflammatory Bowel Disease (IBD), CD - Crohn's Disease
Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD
This comparative observational cohort clinical study aims to investigate the necessity of premedication for allergy prevention prior to infliximab injection, and is designed to evaluate whether non-routine administration of…
- Conditions
- Inflammatory Bowel Disease (IBD), CD - Crohn's Disease, UC - Ulcerative Colitis
- Trial name
- PA (NCT07385131)
- Testing
- Dexamethasone (IV)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Analgesic Adverse Reaction
Psoas Compartment Block (PCB) Versus L.A Infiltration and Remifentanil Infusion During EVAR
Endovascular aneurysm repair (EVAR) was introduced in 1990 for the first time as a minimally invasive procedure instead of the conventional open surgical repair, with the aim to decrease morbidity and mortality .
- Trial name
- NCT03443518
- Testing
- Psoas Compartment Block (PCB), Local Anesthesia infiltration, Normal saline 0.9% IV infusion
- Where
- 2 sites in Saudi Arabia
- Volunteers
- 30 people
- Sponsor
- Dr. Erfan and Bagedo General Hospital
Pompe Disease
Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies
Hypothesis: the effectiveness of treatment of Pompe Disease with rhGAA enzyme replacement therapy (ERT) is limited at least in part because patients develop antibodies against the provided rhGAA enzyme.
- Trial name
- NCT01451879
- Testing
- Rituximab, Miglustat
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Florida
Crohn's Disease, Ulcerative Colitis
Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD)
This study aims to test the hypothesis that the accelerated infusion of infliximab is not inferior to the conventional 2 hour infusion with respect to the frequency of infusion reaction.
- Trial name
- NCT01346826
- Testing
- Standard 2 hours-infusion, Accelerated 1 hour-infusion, Accelerated 30 minutes-infusion
- Where
- South Korea
- Volunteers
- 145 people
- Sponsor
- Asan Medical Center
Infusion Reaction
A Retrospective Cohort Study of Infusion Reactions Due to Vectibix
The purpose of this study is to identify approximately 100 - 150 patients who have received Vectibix (Panitumumab) in offices and clinics located in Tennessee, North Carolina, South Carolina, and North Georgia from February 2004…
- Trial name
- NCT01156090
- Where
- 7 sites in United States
- Volunteers
- 141 people
- Sponsor
- SCRI Development Innovations, LLC
Acute-graft-versus-host Disease, Steroid Refractory Acute Graft Versus Host Disease
Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)
An Early Access Program for patients with steroid refractory acute GvHD after hematopoietic stem cell transplantation. This Program is available for female and male who are recipients of allogenic HSCT and who have been newly…
- Conditions
- Acute-graft-versus-host Disease, Steroid Refractory Acute Graft Versus Host Disease, Graft-versus-host-disease, Graft Vs Host Disease
- Trial name
- NCT03172455
- Testing
- Glassia
- Sponsor
- Impatients N.V. trading as myTomorrows